. 2023 Sep 14;42(1):109–116. doi: 10.1007/s40273-023-01314-2

Table 1.

Groupings of time to death utilities in company base cases for completed NICE technology assessments to October 2022

NICE TA number	Year	Drug	Cancer type
Months: <1, 1–3, 3–6, 6–9, 9–12, 12+^a Days: <30, 30–89, 90–179, 180–269, 270–359, 360+^b
TA319^a	2014	Ipilimumab	Melanoma
TA366^b	2016	Pembrolizumab	Melanoma
TA428 ^b,c,d	2017	Pembrolizumab	NSCLC
Days: <30, 30–89, 90–179, 180+
TA357	2015	Pembrolizumab	Melanoma
Days: <30
TA384^c	2016	Nivolumab	Melanoma
Days: <30, 30–179, 180–359, 360+
TA428^d	2017	Pembrolizumab	NSCLC
TA531	2018	Pembrolizumab	NSCLC
TA557	2018	Pembrolizumab	NSCLC
TA600	2019	Pembrolizumab	NSCLC
TA650	2020	Pembrolizumab	RCC
TA737	2021	Pembrolizumab	Oesophageal/gastro-oesophageal
TA801	2022	Pembrolizumab	Breast
^a Days: <30, 30–99, 100+ ^b Weeks: <4, 4–12, 12+
^a TA517	2018	Avelumab	MCC
^b TA691^d	2021	Avelumab	MCC
Weeks: ≤5, 5–15, 15–30, 30+
TA520	2018	Atezolizumab	NSCLC
TA584	2019	Atezolizumab	NSCLC
TA638^e	2020	Atezolizumab	SCLC
Days: <30, 31–60, 61–90, 91–180, 180–364, 365+
TA661	2020	Pembrolizumab	Head and neck SCC
Days: <35, 35–266, 267+
TA691^d	2021	Avelumab	MCC
Days: <35, 35–74, 75–209, 210+
TA705	2021	Atezolizumab	NSCLC
Days: ≤28, 29–56, 57–84, 84+
TA736	2021	Nivolumab	Head and neck SCC

MCC Merkel cell carcinoma, NSCLC non-small cell lung cancer, NICE National Institute for Health and Care Excellence, RCC renal cell carcinoma, SCC squamous cell carcinoma, SCLC small cell lung cancer, TA technology assessment

^a,bare extremely similar, but differ in being defined by days vs. weeks

^cAlso included progression status as a variable

^dTwo models were included in the submission

^eAlso included a variable for ‘on treatment’

All details taken from publicly available documents hosted on the NICE website, with each TA accessible at https://www.nice.org.uk/guidance/TAXXX by substituting the TA number for ‘XXX’